Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals
申请人:Boehringer Ingelheim Pharma KG
公开号:US20030162788A1
公开(公告)日:2003-08-28
The invention relates to the use of fibrates for lowering the liver toxicity of MTP inhibitors as well as pharmaceutical compositions containing an MTP inhibitor and a fibrate.
2′-bipyridine catalyzed electrochemical cross-coupling reaction between an aryl halide and a chloropyridazine was investigated by an electrochemical study. The electrochemical behavior of the divalent nickel complex is affected by the presence of pyridazine rings which act as co-ligands of nickel. Cyclic voltammetry indicates that the cross-coupling reactioninvolves first a rapid oxidative addition of the chloropyridazine
A general efficient electrochemical method for the preparation of aryl- and heteroarylpyridazines in a nickel-catalyzed cross-coupling reaction of 3-chloro-6-methoxypyridazine and 3-chloro-6-methylpyridazine with a range of functionalized aryl or heteroaryl halides is reported.
KOMBINATION VON MTP INHIBITOREN ODER apoB-SEKRETIONS-INHIBITOREN MIT FIBRATEN ZUR VERWENDUNG ALS ARZNEIMITTEL